Brian C. Cunningham
33Patents
26h-index
30Co-inventors
85Inventor score
Filing activity: Dec 14, 1981 → May 22, 2002
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5834250A | Method for identifying active domains and amino acid residues in polypeptides and hormone variants | Emerging Cross-Sectional Technologies | 206 | Expired |
| US5849535A | Human growth hormone variants | Emerging Cross-Sectional Technologies | 153 | Expired |
| US5534617A | Human growth hormone variants having greater affinity for human growth hormone receptor at site 1 | Emerging Cross-Sectional Technologies | 130 | Expired |
| US5580723A | Method for identifying active domains and amino acid residues in polypeptides and hormone variants | Emerging Cross-Sectional Technologies | 119 | Expired |
| US6057292A | Method for inhibiting growth hormone action | Emerging Cross-Sectional Technologies | 101 | Expired |
| US5700676A | Modified subtilisins having amino acid alterations | Chemistry; Metallurgy | 99 | Expired |
| US6013478A | Method for identifying active domains and amino acid residues in polypeptides and hormone variants | Emerging Cross-Sectional Technologies | 95 | Expired |
| US6451561B1 | Growth hormone variants | Emerging Cross-Sectional Technologies | 82 | Expired |
| US6428954B1 | Method for identifying active domains and amino acid residues in polypeptides and hormone variants | Emerging Cross-Sectional Technologies | 79 | Expired |
| US5506107A | Selecting ligand agonists and antagonists | Physics | 78 | Expired |
| US6800740B1 | Variants of native growth hormones having non naturally occurring amino acid sequences or covalent modifications | Physics | 58 | Expired |
| US6022711A | Human growth hormone variants having enhanced affinity for human growth hormone receptor at site 1 | Emerging Cross-Sectional Technologies | 52 | Expired |
| US5846932A | Receptor specific atrial natriuretic peptides | Human Necessities | 52 | Expired |
| US6143523A | Human growth hormone variants | Emerging Cross-Sectional Technologies | 51 | Expired |
| US5955340A | Modified subtilisins having amino acid alterations | Chemistry; Metallurgy | 49 | Expired |
| US6004931A | Method for inhibiting growth hormone action | Emerging Cross-Sectional Technologies | 46 | Expired |
| US5665704A | Receptor specific atrial natriuretic peptides | Human Necessities | 45 | Expired |
| US5854026A | Human growth hormone variant having enhanced affinity for human growth hormone receptor at site 1 | Emerging Cross-Sectional Technologies | 44 | Expired |
| US6057428A | Variants of vascular endothelial cell growth factor | Physics | 39 | Expired |
| US5763257A | Modified subtilisins having amino acid alterations | Chemistry; Metallurgy | 35 | Expired |
| US5801038A | Modified subtilisins having amino acid alterations | Chemistry; Metallurgy | 32 | Expired |
| US6136563A | Human growth hormone variants comprising amino acid substitutions | Emerging Cross-Sectional Technologies | 29 | Expired |
| US5972682A | Enzymatically active modified subtilisins | Chemistry; Metallurgy | 28 | Expired |
| US5955346A | Variants of human prolactin and human placeatal lactogen | Emerging Cross-Sectional Technologies | 28 | Expired |
| US6525022B1 | Receptor specific atrial natriuretic peptides | Human Necessities | 26 | Expired |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.